YEDA RESEARCH AND DEVELOPMENT
Technology transfer from the Weizmann Institute of Science

Blood Test to Identify People at High Risk for Lung Cancer(No. T4-1033)

Overview
A novel diagnostic test to identify individuals with increased risk of lung cancer

Background and Unmet Need
Lung cancer is the number one killer among cancers, with 160,000 deaths/year in the USA and 1.6 million/year
worldwide. Early detection of lung cancer increases 5-year survival rate from 4% to 54%. Moreover, the National
Lung Cancer Trial (NLST) showed that early detection of lung cancer by low-dose CT reduces mortality by at least
20%. Despite recommendations for low-dose CT screening for heavy smokers fulfilling the NLST criteria,compliance is low. In addition, 80 million smokers and ex-smokers in the US who do not fulfil NLST risk criteria
have no recommended solution.
The MyRepair test fulfils this unmet medical need by providing a quantitative prediction of lung cancer risk using asimple blood test. The test is based on a personalized measurement of the patientâ&#128;&#153;s DNA repair
capacity, a mechanism which is highly connected to the onset of cancer. Therefore, the MyRepair technology canpotentially increase early detection of lung cancer and thus save lives.

The SolutionProf. Livneh's novel biomarker, based on DNA repair assays provides a novel tool for risk assessment and early
detection of lung lancer

Technology Essence
Based on the strong and well documented connection between impaired capacity for DNA repair and onset ofcancer, the Livneh lab invented the MyRepair Test, a method for predicting lung cancer risk, based on measuring
activity of 3 DNA repair enzymes. Combining enzyme activities with experimental risk estimates generated
MyRepair Score, which measures personalized DNA repair capacity of tested subjects.
An epidemiological/clinical study performed in Israel, further validated in an independent UK study, demonstrated
that lung cancer patients have lower MyRepair Score than healthy people. In addition, subjects who test MyRepairpositive have an 85-fold higher risk to develop lung cancer compared to the general population.
Low MyRepair Score is a risk factor independent of smoking, and of comparable magnitude, indicating that it canbe a prognostic tool for smokers, ex-smokers, and non-smokers.

Applications and Advantages
Simplicity â&#128;&#147; MyRepair is based on a simple, cost-effective blood test.
Accessibility â&#128;&#147; Compared to low-dose CT which requires specific equipment, the MyRepair
test can be easily integrated in general diagnostic labs and therefore may be more accessible to a larger
portion of the population.
Additional applications â&#128;&#147; Since the test is based on measuring personalized DNA repair
mechanisms, it can be adopted in the future for the diagnosis of additional cancer types and DNA repairYeda Research & Development Co. Ltd, 95 Rehovot 7610002, Israel Tel. +972.8.9470617
Page 1 of 2

YEDA RESEARCH AND DEVELOPMENT
Technology transfer from the Weizmann Institute of Science
related diseases.
Was recently shown to predict the response of lung cancer patients to immunotherapy!
The suggested technology has the potential to become the gold standard for the long-sought reliable, accurate,simple, safe, cost-effective diagnostic tool to predict lung cancer, and may enable, for the first time, the effective
mass population screening & early diagnostic.

Patent Status
European Patent Office Published: Publication Number: 4014046

Yeda Research & Development Co. Ltd, 95 Rehovot 7610002, Israel Tel. +972.8.9470617
Page 2 of 2